Biotechnology company Moderna released a coronavirus vaccine trial plan Thursday as enrollment in their final trial pushes toward 30,000 people.
The top vaccine candidate said the trial has now enrolled 25,296 of an expected 30,000 volunteers, and more than 10,000 of them have received two doses of the vaccine.
“We believe this is unprecedented times. There’s a lot of suffering from a public health standpoint,” Moderna CEO Stephane Bancel told CNBC Thursday. “If Moderna’s vaccine were to get a good safety readout and a good efficacy readout and be approved by the agency, we care deeply that this vaccine is trusted.”
Bancel added in the interview that the company will know by November if its vaccine will be ready to deploy by the end of the year.
"If the infection rate in the country were to slow down in the next weeks, it could potentially be pushed out in a worst-case scenario in December,” Bancel said.
Her comments come as President TrumpDonald TrumpWendy Sherman takes leading role as Biden's 'hard-nosed' Russia negotiator Senate needs to confirm Deborah Lipstadt as antisemitism envoy — Now Former acting Defense secretary under Trump met with Jan. 6 committee: report MORE has asserted that a vaccine could be ready before Election Day, while Democrats including Sen. Kamala HarrisKamala HarrisSecond gentleman Emhoff acts as public link to White House Harris takes fresh start to 2022 We are America's independent contractors, and we are terrified MORE (D-Calif.), the party's vice presidential nominee, have said that they would wait for top health experts to speak for the efficacy of a vaccine before taking it.
“We’re very close to that vaccine as you know and I think much closer than I think most people want to say,” Trump recently told reporters during a White House press briefing. “We think we can start some time in October. So as soon as it’s announced we’ll be able to start. That will be from mid-October on. It may be a little bit later than that.”
The company also announced plans Thursday in a press release to develop a seasonal flu vaccine, which the company said was in response to "the unmet need for highly effective vaccines."
"We are actively preparing for a potential commercial launch of mRNA-1273, our COVID-19 vaccine, and we continue to expand the breadth of Moderna’s platform,” the company said.